Relationship between tumor biomarkers (BM) and efficacy in TH3RESA, a phase 3 study of trastuzumab emtansine (T-DM1) versus treatment of physician’s choice (TPC) in HER2-positive advanced breast cancer (BC) previously treated with trastuzumab and lapatinib.

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70178-0 ◽

2014 ◽

Vol 15 (7) ◽

pp. 689-699 ◽

Cited By ~ 350

Author(s):

Ian E Krop ◽

Sung-Bae Kim ◽

Antonio González-Martín ◽

Patricia M LoRusso ◽

Jean-Marc Ferrero ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Faculty Opinions recommendation of Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718373656.793494835 ◽

2014 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Abstract P4-14-01: Trastuzumab emtansine improves overall survival versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer: Final results from the phase 3 EMILIA study

10.1158/1538-7445.sabcs15-p4-14-01 ◽

2016 ◽

Author(s):

V Diéras ◽

D Miles ◽

S Verma ◽

M Pegram ◽

M Welslau ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Phase 3 ◽

Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1)vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer

International Journal of Cancer ◽

10.1002/ijc.30276 ◽

2016 ◽

Vol 139 (10) ◽

pp. 2336-2342 ◽

Cited By ~ 36

Author(s):

Sung-Bae Kim ◽

Hans Wildiers ◽

Ian E. Krop ◽

Melanie Smitt ◽

Ron Yu ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Phase Iii ◽

Tumor Biomarkers ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Phase Iii Study ◽

Abstract S5-05: Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase 3 TH3RESA study

10.1158/1538-7445.sabcs15-s5-05 ◽

2016 ◽

Cited By ~ 8

Author(s):

H Wildiers ◽

S-B Kim ◽

A Gonzalez-Martin ◽

PM LoRusso ◽

J-M Ferrero ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Phase 3 ◽

Previously Treated ◽

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

BMC Cancer ◽

10.1186/s12885-019-5831-x ◽

2019 ◽

Vol 19 (1) ◽

Author(s):

Edith A. Perez ◽

Sanne Lysbet de Haas ◽

Wolfgang Eiermann ◽

Carlos H. Barrios ◽

Masakazu Toi ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Phase Iii ◽

Tumor Biomarkers ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Phase Iii Study

Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00332-0 ◽

2015 ◽

Vol 16 (15) ◽

pp. 1556-1568 ◽

Cited By ~ 51

Author(s):

Edith A Perez ◽

Ahmad Awada ◽

Joyce O'Shaughnessy ◽

Hope S Rugo ◽

Chris Twelves ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Open Label ◽

Phase 3 ◽

Multicentre Phase ◽

Previously Treated ◽

Etirinotecan Pegol ◽

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

BMC Cancer ◽

10.1186/s12885-019-5687-0 ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 10

Author(s):

Edith A. Perez ◽

Sanne Lysbet de Haas ◽

Wolfgang Eiermann ◽

Carlos H. Barrios ◽

Masakazu Toi ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Phase Iii ◽

Tumor Biomarkers ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Phase Iii Study

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30465-4 ◽

2020 ◽

Vol 21 (10) ◽

pp. 1283-1295 ◽

Cited By ~ 1

Author(s):

Leisha A Emens ◽

Francisco J Esteva ◽

Mark Beresford ◽

Cristina Saura ◽

Michelino De Laurentiis ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Trastuzumab Emtansine ◽

Phase 2 ◽

Double Blind Trial ◽

Her2 Positive ◽

Double Blind ◽

Blind Trial ◽

Exposure–response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-017-3440-4 ◽

2017 ◽

Vol 80 (6) ◽

pp. 1079-1090 ◽

Cited By ~ 7

Author(s):

Chunze Li ◽

Bei Wang ◽

Shang-Chiung Chen ◽

Russell Wada ◽

Dan Lu ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Exposure Response ◽